Kaneka Corporation has installed continuous manufacturing equipment to be applied to pharmaceutical products at Kaneka Singapore Co. Ltd, with commercial production under cGMP already underway as of June 2018.
In the field of small molecule pharmaceutical products, the recent demands have begun to trend toward an increased number of more diversified and smaller volume targets. With these changes, more efficient production technology is needed to address the broad range of targets now required. The installed equipment is a Kaneka designed reactor that allows diversity of application through the ability to select the relevant parameters of the reaction tubing based on laboratory and scale-up research providing the highest performance of reactions.
Kaneka has capability from process development to commercial production with excellent quality assurance, and now aim to expand our solution services in the Health Care business field utilizing this new technology.
